Biolynx’s new generation antibody development platform - the Recombinant Rabbit Monoclonal Antibody Development Technology Platform (R2mAb®), is based on the unique molecular mechanism of the rabbit’s immune system, which has the capacity to produce various antibodies compared to other species. The R2mAb® platform utilizes a method of genetic engineering for antibody genes’recombinant expression in mammalian cells. Antibodies produced on the platform can be engineered and optimized for performance according to intended use and become ideal rabbit monoclonal antibodies.
Cervix, Cervix Cancer and Colon were selected for p63 as positive and negative control tissue.
Potential products were validated on mainstream IHC stainerguaranteed the performance at clinic.